Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± ipilimumab vs placebo as maintenance in extensive-stage small cell lung cancer after first-line chemotherapy
jRCT2080223037Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Nivolumab maintenance, Nivolumab + ipilimumab maintenance and Placebo maintenance (3 arms). Started Dec 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080223037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223037.